跳到正文
ACS Nano· Xue·· 6 天前精选AI 评分61

遮蔽并放大的纳米颗粒疫苗重定向免疫优势,拓宽对 SARS-CoV-2 变异株的保护

Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2

AI 导读

研究者在 ACS Nano 发表一种模块化“shield-and-amplify”纳米颗粒疫苗策略,通过在 RBD 上引入位点特异性 N-连接聚糖遮蔽易变的免疫优势区、保留 class 5 表位,并经 nanobody 介导组装展示在 p239 纳米颗粒上形成 RGM@p239。

AI 深度导读基于原文整理的分节解读
背景
抗原变异严重限制了疫苗对快速演化病毒的保护持久性与广度。保守表位本可支撑跨变异株免疫,但针对病毒糖蛋白的抗体应答常偏向暴露且易变的免疫优势表位,使保守的保护位点处于次优势地位。作者此前已在 SARS-CoV-2 受体结合域(RBD)上鉴定出一个隐蔽的保守 class 5 表位(6D6/7D6 表位),该表位能够引发广谱交叉中和。
做法
作者提出模块化的“屏蔽—放大”(shield-and-amplify)纳米颗粒疫苗接种策略,把免疫优势重新导向这一层次要的保守表位。具体做法是在 RBD 上设计位点特异的 N-连接聚糖,与天然 N343 聚糖一起遮蔽易变的免疫优势区域,同时保留 class 5 表位的可及性,由此得到聚糖遮蔽 RBD 抗原 RGM。RGM 再通过纳米抗体介导的组装展示在 p239 纳米颗粒上,形成多价免疫原 RGM@p239。作者随后对抗原谱进行了分析,比较 6D6、7D6 抗体与代表性 class 1–4 抗体的结合情况。
结论
抗原谱分析显示,聚糖屏蔽保留了 6D6 与 7D6 抗体的识别,同时使代表性 class 1–4 抗体的结合下降至少 80%。在免疫动物中,RGM@p239 富集了与 7D6 竞争的血清抗体,这些抗体可阻断约 70–80% 的血清与 RGM 的结合,并拓宽了对 8 株代表性变异株的交叉中和,其中包括对 Omicron 谱系可检测到的活性。在仓鼠模型中,RGM@p239 降低了 Omicron EG.1 攻击后的疾病严重程度。
意义
结果支持这样一个模型:聚糖屏蔽与纳米颗粒多价性作为互补的免疫聚焦模块发挥作用——屏蔽削弱竞争性应答,多价性则放大对保守次优势表位的应答。作者据此提出一种以纳米疫苗设计应对抗原变异的策略,思路是把免疫应答聚焦到病毒保守的脆弱位点上。

原文摘要

出版方登记 · Crossref

Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

本页是 AI 精读,不转载论文原文;完整论文(含方法、图表与参考文献)见原文

推荐理由

用聚糖遮蔽加纳米颗粒多价展示把免疫应答引向保守的 class 5 表位,为广谱疫苗设计提供一个可复用的模块。

来源:ACS Nano · doi.org